SEC Tracker
Get the app

BridgeBio Oncology Therapeutics BBOT

BridgeBio Oncology Therapeutics reported Q3 2026 results

BridgeBio Oncology Therapeutics (BBOT) filed an 8-K with the SEC on Nov 10, 2026, 4:19 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash position of $315.3 million expected to fund operations into 2029
  2. Net loss of $34.2 million for Q3 2026, down from $44.8 million in Q3 2025
  3. BBO-8520 plus pembrolizumab showed 75% ORR in KRASG12C inhibitor-experienced NSCLC patients

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when BridgeBio Oncology Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.